- Conditions
- Advanced Solid Tumors
- Interventions
- ASP8374, Pembrolizumab
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 169 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 19
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Sacramento, California + 14 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Leukemia
- Interventions
- nelarabine
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 16 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2004
- U.S. locations
- 107
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 69 more
- Conditions
- Hepatitis C, Hepatitis C, Chronic
- Interventions
- thymalfasin (thymosin alpha 1) + PEGinterferon alfa-2a, placebo + PEGinterferon alfa-2a
- Drug
- Lead sponsor
- SciClone Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 46
- States / cities
- Mobile, Alabama • Scottsdale, Arizona • Berkeley, California + 36 more
- Conditions
- Alzheimer Disease
- Interventions
- Gantenerumab, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 975 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 47
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Fayetteville, Arkansas + 39 more
- Conditions
- Hodgkin Disease
- Interventions
- Nivolumab, brentuximab vedotin, bendamustine
- Biological
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 5 Years to 30 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 43
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 40 more
- Conditions
- Colorectal Cancer
- Interventions
- Nivolumab, Oxaliplatin, Leucovorin, Fluorouracil, Bevacizumab
- Biological · Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 196 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 35
- States / cities
- Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 29 more
- Conditions
- Arterial Disease of Legs, Below-the-knee Obstruction, PAD - Peripheral Arterial Disease
- Interventions
- MagicTouch PTA Sirolimus drug coated balloon, Placebo balloon angioplasty
- Device
- Lead sponsor
- Concept Medical Inc.
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 368 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 29
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Clearwater, Florida + 22 more
- Conditions
- Retinitis Pigmentosa
- Interventions
- N-acetylcysteine, Placebo
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 485 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 24
- States / cities
- Davis, California • Los Angeles, California • San Francisco, California + 21 more
- Conditions
- Type 2 Diabetes, Cardiovascular Disease
- Interventions
- TAK-875, TAK-875 Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,207 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 218
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 215 more
- Conditions
- Metastatic Pancreatic Adenocarcinoma
- Interventions
- BBI608, Nab-paclitaxel, Gemcitabine, Oxaliplatin, Leucovorin, Irinotecan, Fluorouracil, MM-398
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 139 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Atlanta, Georgia • Fort Wayne, Indiana + 9 more
- Conditions
- Hepatitis C, Chronic
- Interventions
- Ribavirin (RBV), BI 201335 (Faldaprevir), BI 207127, Faldaprevir (BI 201335)
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 470 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 24
- States / cities
- Dothan, Alabama • Chula Vista, California • La Mesa, California + 19 more
- Conditions
- Chronic Kidney Diseases
- Interventions
- Ferric Citrate, Placebo
- Drug
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 6 Years to 18 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 18
- States / cities
- Los Angeles, California • Orange, California • San Francisco, California + 14 more
- Conditions
- Peanut Allergy
- Interventions
- Viaskin Peanut 250 mcg, Placebo
- Biological
- Lead sponsor
- DBV Technologies
- Industry
- Eligibility
- 4 Years to 11 Years
- Enrollment
- 393 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 26
- States / cities
- Little Rock, Arkansas • Mission Viejo, California • Rolling Hills Estates, California + 21 more
- Conditions
- Radiologically Isolated Syndrome, Multiple Sclerosis
- Interventions
- Observational
- Other
- Lead sponsor
- Centre Hospitalier Universitaire de Nīmes
- Other
- Eligibility
- Not listed
- Enrollment
- 320 participants
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Healthy Adult Subjects
- Interventions
- Omaveloxolone, Midazolam oral solution, Repaglinide 1 MG, MetFORMIN 500 Mg Oral Tablet, Rosuvastatin, Digoxin tablet, Gemfibrozil Tablets, Itraconazole capsule, Verapamil Pill
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 61 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Emergency General Surgery
- Interventions
- Emergency general surgery
- Procedure
- Lead sponsor
- Methodist Health System
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Moderate to Severe Plaque Psoriasis
- Interventions
- Placebo, SCD-044_Low Dose (Dose 1), SCD-044_Intermediate Dose (Dose 2), SCD-044_High Dose (Dose 3)
- Drug
- Lead sponsor
- Sun Pharmaceutical Industries Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 263 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 29
- States / cities
- Yuma, Arizona • Encino, California • Los Angeles, California + 20 more
- Conditions
- Idiopathic Inflammatory Myopathies
- Interventions
- Rapcabtagene autoleucel, Active Comparator Option
- Biological · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 123 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2032
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • Zephyrhills, Florida • Chicago, Illinois + 6 more
- Conditions
- Cocaine Dependence
- Interventions
- Buspirone, Placebo
- Drug
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 6
- States / cities
- Jacksonville, Florida • Columbus, Ohio • Philadelphia, Pennsylvania + 3 more
- Conditions
- Marburg Virus Disease
- Interventions
- cAd3-Marburg Vaccine, Placebo
- Biological
- Lead sponsor
- Albert B. Sabin Vaccine Institute
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 7
- States / cities
- Huntsville, Alabama • Phoenix, Arizona • Melbourne, Florida + 4 more
- Conditions
- Dry Age-related Macular Degeneration, Geographic Atrophy, Macular Degeneration, Retinal Disease, Retinal Degeneration
- Interventions
- GEM103
- Drug
- Lead sponsor
- Gemini Therapeutics, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 29
- States / cities
- Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 26 more
- Conditions
- Advanced Solid Tumors, Ovarian Cancer, Endometrial Cancer, Cholangiocarcinoma, CNS Tumor
- Interventions
- PHST001, Chemotherapy per Standard of Care
- Biological · Drug
- Lead sponsor
- Pheast Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 272 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 20
- States / cities
- Beverly Hills, California • Los Angeles, California • Palo Alto, California + 15 more
- Conditions
- Leukemia, Myeloid, Acute
- Interventions
- Cytarabine, Idasanutlin, Placebo
- Drug · Other
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 447 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 7
- States / cities
- Great Neck, New York • Hawthorne, New York • New York, New York + 3 more
- Conditions
- Esophageal Neoplasms, Adenocarcinoma of the Gastroesophageal Junction, Gastroesophageal Cancer, Squamous Cell Carcinoma, Gastric Adenocarcinoma
- Interventions
- DKN-01 150 mg, Paclitaxel, Pembrolizumab, DKN-01 300 mg
- Drug
- Lead sponsor
- Leap Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 151 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 10
- States / cities
- Los Angeles, California • New Haven, Connecticut • Chicago, Illinois + 5 more